Pathophysiologic Mechanisms of Selected Types of Nephrotoxicity

Back

Aminoglycoside Nephrotoxicity

Aminoglycosides preferentially affect the proximal tubular cells. These agents are freely filtered by the glomeruli and quickly taken up by the proximal tubular epithelial cells, where they are incorporated into lysosomes after first interacting with phospholipids on the brush border membranes. They exert their main toxic effect within the tubular cell by altering phospholipid metabolism. In addition to their direct effect on cells, aminoglycosides cause renal vasoconstriction.

The 2 critical factors in the development of acute kidney injury (AKI) secondary to aminoglycoside nephrotoxicity are dosing and duration of therapy. Approximately 5% of the administered dose accumulates within epithelial cells after glomerular filtration.[1] Aminoglycoside uptake by the tubules is a saturable phenomenon, so uptake is limited after a single dose. Thus, a single daily large dose is preferable to 3 doses per day. One dose per day presumably causes less accumulation in the tubular cells once the saturation point is reached.[2, 3]

Extending the dose interval to > 24 hours in patients with renal impairment has been found effective, with irreversible nephrotoxicity reported in approximately 1% of the patients studied.[4]

For further information, go to Acute Kidney Injury and Acute Tubular Necrosis.

Amphotericin B Nephrotoxicity

Amphotericin B binds to sterols in cell membranes, thereby creating pores that compromise membrane integrity and increase membrane permeability. It binds not only to ergosterol in fungal cell walls but also to cholesterol in human cell membranes; this is what accounts for its nephrotoxicity.

Characteristic electrolyte abnormalities include wasting of potassium and magnesium secondary to increased permeability of the cell membranes. The back-leak of hydrogen ions in the collecting duct leads to distal renal tubular acidosis (dRTA).[5, 6]

Lipid-based preparations of amphotericin B decrease but do not eliminate the nephrotoxicity compared with traditional amphotericin B.[7] This may be due to a direct nephrotoxic effect of the conventional preparation.

For further information, go to Acute Kidney Injury and Acute Tubular Necrosis.

Contrast-Induced Nephropathy

Although the pathogenesis of contrast-induced nephropathy (CIN) remains incompletely understood, it is most likely the result of renal vasoconstriction and direct renal tubular epithelial cell toxicity. Current theories regarding CIN include a combination of direct cytotoxicity with postischemic reperfusion injury resulting in oxygen free radical production leading to endothelial damage.[8, 9, 10]

For further information, go to Contrast-Induced Nephropathy.

Calcineurin Inhibitor Nephrotoxicity

Cyclosporine and tacrolimus cause acute kidney injury (AKI) by inducing afferent and efferent arteriolar vasoconstriction. Persistent injury can lead to interstitial fibrosis. Tacrolimus has been shown to cause thrombotic microangiopathy as a result of endothelial injury.[11, 12]

While the mechanisms underlying cyclosporine nephrotoxicity are still not fully understood, increasing lines of evidence suggest that oxidative stress plays an important role in this phenomenon. Specifically, cyclosporine induces endoplasmic reticulum stress and increases mitochondrial reactive oxygen species production: this modifies the redox balance, which causes lipid peroxidation and thereby induces nephrotoxicity.[13]

For further information, go to Acute Kidney Injury and Acute Tubular Necrosis.

Cisplatin Nephrotoxicity

Cisplatin usually affects the proximal tubules primarily, with some secondary effect on the glomeruli and distal tubules. Cisplatin is excreted primarily in the urine, resulting in concentrated drug levels, which encourage uptake into the cells by passive diffusion or active uptake. Cisplatin is stable in the bloodstream but becomes hydrolyzed in the chloride-poor cellular environment. It is the hydrolyzed metabolite that binds DNA, RNA, proteins, and phospholipids, causing cytotoxicity.[14]

PRKCD/PKCδ (protein kinase C delta) may have a role in cisplatin-induced nephrotoxicity by suppressing macroautophagy/autophagy, a cytoprotective mechanism, to promote kidney tubule cell death during cisplatin treatment. PRKCD may do so by phosphorylating AKT, which further phosphorylates MTOR to repress ULK1.[15]

For further information, go to Acute Kidney Injury and Acute Tubular Necrosis.

Ifosfamide Nephrotoxicity

Ifosfamide is a known analog of cyclophosphamide. Although cyclophosphamide is not nephrotoxic, ifosfamide, by virtue of its metabolite chloroacetaldehyde, is toxic to the tubular cells, with preferential involvement of the proximal tubule leading to Fanconi syndrome.[16, 17]

For further information, go to Acute Kidney Injury and Acute Tubular Necrosis.

Foscarnet Nephrotoxicity

Foscarnet, which is used to treat resistant cytomegalovirus (CMV) infections, causes acute interstitial nephritis and intratubular crystal formation. In addition to formation of crystals, which can be made up of calcium salts or sodium salts, chelation of calcium by foscarnet leads to hypocalcemia.[18, 19]

For further information, go to Acute Kidney Injury and Acute Tubular Necrosis.

Crystal-Forming Drug Nephrotoxicity

Sulfa drugs, acyclovir, methotrexate, ethylene glycol, and protease inhibitors such as indinavir cause acute kidney injury (AKI) by tubular obstruction due to crystal formation in the tubular urine.

Acyclovir may lead to the formation of intratubular crystals, which appear as birefringent needle-shaped crystals and can elicit an acute interstitial nephritis.[20, 21]

For further information, go to Acute Kidney Injury and Acute Tubular Necrosis.

Rhabdomyolysis

Rhabdomyolysis refers to the breakdown of skeletal muscle fibers, which leads to the release of potentially nephrotoxic intracellular contents into the circulation. Acute kidney injury (AKI) develops in this setting via the following 3 mechanisms:

Heme proteins are believed to be involved in the generation of reactive oxygen species (ROS), which are known to cause tubular injury through peroxidation of membrane lipids and intracellular enzymes.[22]

For further information, go to Acute Kidney Injury and Acute Tubular Necrosis.

Multiple Myeloma

Multiple myeloma causes kidney injury by several mechanisms. The extra protein can be deposited in the kidney as amyloidosis or monoclonal immunoglobulin deposition disease affecting the glomeruli. Light-chain cast nephropathy occurs when light chains become concentrated in the tubular lumen. Plasma cells can infiltrate the kidney directly, causing kidney dysfunction. Hypercalcemia can independently cause renal vasoconstriction. Volume depletion and medications used to treat multiple myeloma can also contribute to kidney disease.[23, 24]

For further information, go to Acute Kidney Injury and Acute Tubular Necrosis.

Author

Piper Julie Hughes, MD, MS, Resident Physician, Department of Internal Medicine, Vidant Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Edgar V Lerma, MD, FACP, FASN, FAHA, FASH, FNLA, FNKF, Clinical Professor of Medicine, Section of Nephrology, Department of Medicine, University of Illinois at Chicago College of Medicine; Research Director, Internal Medicine Training Program, Advocate Christ Medical Center; Consulting Staff, Associates in Nephrology, SC

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Astra Zeneca<br/>Author for: UpToDate, ACP Smart Medicine, Elsevier, McGraw-Hill, Wolters Kluwer.

Tejas Desai, MD, Staff Nephrologist, WG (Bill) Hefner VA Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Vecihi Batuman, MD, FASN, Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System

Disclosure: Nothing to disclose.

Acknowledgements

Mahendra Agraharkar, MD, MBBS, FACP, FASN Clinical Associate Professor of Medicine, Baylor College of Medicine; President and CEO, Space City Associates of Nephrology

Mahendra Agraharkar, MD, MBBS, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Nephrology, and National Kidney Foundation

Disclosure: South Shore DaVita Dialysis Center Ownership interest/Medical Directorship Other; Space City Dialysis /American Renal Associates Ownership/Medical Directorship Same; US Renal Care Ownership interest Other

George R Aronoff, MD Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

F John Gennari, MD Associate Chair for Academic Affairs, Robert F and Genevieve B Patrick Professor, Department of Medicine, University of Vermont College of Medicine

F John Gennari, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Federation for Medical Research, American Heart Association, American Physiological Society, American Society for Clinical Investigation, American Society of Nephrology, and International Society of Nephrology

Disclosure: Nothing to disclose.

Brent Kelly MD Assistant Professor, Department of Dermatology, University of Texas Medical Branch, Galveston, Texas

Brent Kelly is a member of the following medical societies: Alpha Omega Alpha and American Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References

  1. McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. Pediatr Nephrol. 2017 Nov. 32 (11):2015-2025. [View Abstract]
  2. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011 Jan. 79(1):33-45. [View Abstract]
  3. Rougier F, Claude D, Maurin M, Maire P. Aminoglycoside nephrotoxicity. Curr Drug Targets Infect Disord. 2004 Jun. 4(2):153-62. [View Abstract]
  4. Plajer SM, Chin PK, Vella-Brincat JW, Buffery PJ, Begg EJ. Gentamicin and renal function: lessons from 15 years' experience of a pharmacokinetic service for extended interval dosing of gentamicin. Ther Drug Monit. 2015 Feb. 37 (1):98-103. [View Abstract]
  5. Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010 Jul. 89(4):236-44. [View Abstract]
  6. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol. 2004 Jul. 26(7):421-6. [View Abstract]
  7. Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012 Jun. 54(12):1774-7. [View Abstract]
  8. Lencioni R, Fattori R, Morana G, Stacul F. Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT) - a clinical problem in daily practice? A multicenter observational study. Acta Radiol. 2010 Sep. 51(7):741-50. [View Abstract]
  9. Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant. 2005 Aug. 20(8):1542-50. [View Abstract]
  10. Azzalini L, Spagnoli V, Ly HQ. Contrast-Induced Nephropathy: From Pathophysiology to Preventive Strategies. Can J Cardiol. 2016 Feb. 32 (2):247-55. [View Abstract]
  11. Lee JP, Heo NJ, Joo KW, Yi NJ, Suh KS, Moon KC, et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant. 2010 Aug. 25(8):2772-85. [View Abstract]
  12. Hamour IM, Omar F, Lyster HS, Palmer A, Banner NR. Chronic kidney disease after heart transplantation. Nephrol Dial Transplant. 2009 May. 24(5):1655-62. [View Abstract]
  13. Wu Q, Wang X, Nepovimova E, Wang Y, Yang H, Kuca K. Mechanism of cyclosporine A nephrotoxicity: Oxidative stress, autophagy, and signalings. Food Chem Toxicol. 2018 Aug. 118:889-907. [View Abstract]
  14. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2010 Nov. 2(11):2490-518. [View Abstract]
  15. Zhang D, Xu X, Dong Z. PRKCD/PKCδ contributes to nephrotoxicity during cisplatin chemotherapy by suppressing autophagy. Autophagy. 2017 Mar 4. 13 (3):631-632. [View Abstract]
  16. Chen N, Aleksa K, Woodland C, Rieder M, Koren G. The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells. Transl Res. 2007 Jul. 150(1):51-7. [View Abstract]
  17. Nissim I, Horyn O, Daikhin Y, Nissim I, Luhovyy B, Phillips PC, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006 Aug 1. 66(15):7824-31. [View Abstract]
  18. Deray G, Martinez F, Katlama C, Levaltier B, Beaufils H, Danis M, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 1989. 9(4):316-21. [View Abstract]
  19. Maurice-Estepa L, Daudon M, Katlama C, Jouanneau C, Sazdovitch V, Lacour B, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis. 1998 Sep. 32(3):392-400. [View Abstract]
  20. Rho M, Perazella MA. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr Drug Saf. 2007 May. 2(2):147-54. [View Abstract]
  21. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005 May. 45(5):804-17. [View Abstract]
  22. Zager RA, Johnson AC, Lund S, Hanson S. Acute renal failure: determinants and characteristics of the injury-induced hyperinflammatory response. Am J Physiol Renal Physiol. 2006 Sep. 291(3):F546-56. [View Abstract]
  23. Batuman V. The pathogenesis of acute kidney impairment in patients with multiple myeloma. Adv Chronic Kidney Dis. 2012 Sep. 19(5):282-6. [View Abstract]
  24. Prakash J, Niwas SS, Parekh A, Vohra R, Wani IA, Sharma N, et al. Multiple myeloma--presenting as acute kidney injury. J Assoc Physicians India. 2009 Jan. 57:23-6. [View Abstract]